CC
NRIX icon

Corton Capital’s Nurix Therapeutics NRIX Stock Holding History

Corton Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,375
Closed -$402K – 675
2024
Q1 		$402K Sell
27,375
-12,478
-31% -$134K 0.15% 184
2023
Q4 		$411K Buy
39,853
+13,289
+50% +$91.1K 0.13% 217
2023
Q3 		$209K Sell
26,564
-1,049
-4% -$9.58K 0.11% 303
2023
Q2 		$276K Buy
+27,613
New +$282K 0.13% 234

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Corton Capital's NRIX Position: Q2 2024 in Review

Corton Capital sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 27,375 shares — an estimated $402K sold.

Corton Capital first reported a position in NRIX in Q2 2023 and held it in 4 quarters. The position peaked at $411K in Q4 2023. 173 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

  • Corton Capital reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Corton Capital sold 27,375 Nurix Therapeutics shares in Q2 2024, an estimated $402K.
  • Corton Capital first reported a position in Nurix Therapeutics in Q2 2023 and held it in 4 quarters.
  • Corton Capital's Nurix Therapeutics position peaked at $411K in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on Corton Capital's 13F filing for Q2 2024, filed 14 Aug 2024.